Baird lowered the firm’s price target on Quest Diagnostics to $136 from $140 and keeps a Neutral rating on the shares. The firm said the outlook is effectively flat for the year ahead and there are positive macro themes, but also regulatory and reimbursement uncertainties.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on DGX:
- Quest Diagnostics Announces 5.6% Quarterly Dividend Hike
- Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
- Notable companies reporting before tomorrow’s open
- DGX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Quest Diagnostics price target lowered to $152 from $153 at JPMorgan
